The lawsuit, filed Friday in a Delaware federal court, claims that Pfizer will violate 40 patents by selling a copy of Roche’s breast cancer drug. In addition, if Pfizer launches its product in the U.S. before Herceptin patents expire, Roche is seeking compensation for any lost revenue.
Roche’s Herceptin, which was approved by the FDA in 1998, uses an antibody to target the mechanism that makes breast cancer aggressive. Pfizer is currently looking for FDA approval for its proposed biosimilar of Herceptin, called PF-05280014.
“We will respond in court at the appropriate time,” Pfizer spokesman Thomas Biegi told Bloomberg. “We’re committed to making this important treatment option available to physicians and patients.”
In recent years, Roche Holdings has been facing increased pressure as cheaper biosimilars of its complex cancer medicines enter into the market, chipping away at its revenue.
More articles on supply chain:
4 ways the FDA is addressing the saline bag shortage
FDA approves first pill with digital ingestion tracking system
Mylan lays off up to 300 employees
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
